期刊文献+

多发性硬化患者中IL-12和孕酮的检测及其临床意义 被引量:1

The assay and its clinical significance about progesterone and interleukin-12 in the patients with multiple sclerosis
原文传递
导出
摘要 目的检测IL-12和孕酮在多发性硬化(MS)患者中的水平,探讨男、女性多发性硬化患者存在的发病机制,比较男、女性MS患者在临床上发病的差异。方法采用酶联免疫(ELISA)法检测60例MS患者的脑脊液和40例患者血液中IL-12的水平,应用放射免疫法测定40例MS患者血液中孕酮的含量,并与40例正常对照组比较(以上标本男女各半)。结果男、女性MS患者血液中和脑脊液IL-12的含量明显高于正常对照组(P<0.01);女性患者血液中孕酮的含量明显低于正常对照组(P<0.01),男性患者血液中孕酮的含量与正常对照组差别不明显(P>0.05);女性患者血液中孕酮对IL-12的含量存在负相相关作用(r=-0.80,P<0.01),男性相关作用不明显(r=-0.38,P>0.05)。结论IL-12参与多发性硬化的发病过程;孕酮可能是男、女性患者发病差异性的原因之一。 Objective To detect the contents of IL-12 and progesterone and probe into the pathogenesis in the patients and compare the difference between male and female patients with multiple sclerosis. Methods IL-12 in the CSF with 60 patients and blood serum with 40 patients was assessed by enzyme-linked immunosorbent assay (ELISA) and progesterone in the blood serum with 40 patients by radio-immunity(RI). We compared them with the 40 control subjects and half of them were male patients. Results The levels of IL-12 in CSF and blood serum were significantly higher in the patients than those in the controls(P〈0. 01 ) The progesterone of blood serum in the female patients was significantly lower than that in the control(P〈0. 01 ). There was no significant difference in the progesterone level between the male patients and the controls(P〈0. 05 ). There was negative correlation between progesterone and IL-12 in the blood serum of female patients (r = - 0. 80,P〈0. 01 ). The correlation about male patients is not obvious(r= - 0. 38,P〈0. 05) o Conclusions IL-12 may have an important rate in the patbogenesis of MS and progesterone may be one of the causes of difference between males and female patients.
出处 《卒中与神经疾病》 2006年第5期284-286,共3页 Stroke and Nervous Diseases
关键词 白细胞介素-12 孕酮 多发性硬化 Interleukin-12 Progesterone Multiple sclerosis
  • 相关文献

参考文献8

  • 1辛晋敏.干扰素-β治疗多发性硬化—IL-12抑制是关键[J].大同医学专科学校学报,2001,21(3):25-26. 被引量:1
  • 2Ilia J.Elenkov R,Wilder,et al.IL-12,TNF-a,and hormonal changes during late pregnancy and early postpartum:Implications for autoimmue disease activity during these times.The Journal of Clinical Endocrinology,2001,86 (10):4933-4938.
  • 3Itzhak M,Kannan N,Avraham B,et al.A novel protective model against experimental allergic encephalomyelitis in mice expressing a transgenic TCR-specific myelin oligodendrocyte glycoprotein.Journal of Neuroimmunology,2003,144:28-37.
  • 4Itzhak M,Ethan M.Shevach.Differentiated Th1 autoreactive effector cells can induce experimental autoimmune encephalomyelitis in the absence of IL-12 and CD40/CD40L interactions.Journal of Neuroirnmunology,2002,122:65-73.
  • 5de Goerde Herve MG,Delfraissy JF,Taoufik Y.Following direct CD40 activation,human primary microglial cells produce IL-12 p40 but not bioactive IL-12 p70.academic press,2001,1 (8):1043-4666.
  • 6Yassir H,Alessandra S,Mats S,et al.Glatirameracetate and IFN-β act on dendritic cells in multiple sclerosis.Journal of Neuroimmunology,2001,121:102-110.
  • 7Kenneth W.Beagley,Christine M.Regulation of innate and adaptive immunity by the female sexhormones oestradiol and progesterone FEMS.Immunology and Medical Microbiology,2003,38:13-22.
  • 8Van Weyenbergh J,da Purificac M,Silva P,et al.IFN-β and TGF-β differentially regulate IL-12 activity in human peripheral blood mononuclear cells.Immunology.Letters,2001,75:117-122.

同被引文献20

  • 1Kcegan BM, Noscworthy JH. Multiple sclerosis [ J ]. Annu Rev Med ,2002,53 ( 13 ) :285-302.
  • 2Martinez-Caceres EM, Barrau MA, Brieva L, et al. Treatment with methylprednisolone in relapses of muhiple sclerosis patients : immu- nological evidence of immediate and short-team but not long lasting effects [ J ]. Clin Exp Immunol, 2002,127 ( 1 ) : 165-171.
  • 3Oliveri RL, Sibilia G, Valentino P, et al. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing remitting multiple sclerosis [ J ]. Acta Neurol Scand, 1998,97 (6) :366-369.
  • 4Durelli L, Barbero P, Bergui M ,et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in muhiple sclerosis [ J ]. J Neurol Neurosurg Psychiatry, 2008,79 (6) :646-651.
  • 5Kappos L, Freedman MS, Polman CH,et al. Long-term effect of early treatment with interfernon beta-lb after a first clinical event suggestive of multiple sclerosis :5-year active treatment extension of the phase 3 BENEFIT trial [ J]. Lancet Neurol, 2009,8 ( 11 ) : 987-997.
  • 6Coppola G, Lanzillo R, Florio C, et al. Long-rerm clinical experience with weekly interferon beta-1 a in relapsing multiple sclerosis [ J]. Eur J Neurol,2006,13 (9) : 1014-1021.
  • 7Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS : a comparison between the three products [ J ]. Neurology,2004,62 (4) :628-631.
  • 8Blanco Y, Moral EA, Costa M, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis : a longitudinal study [ J ].Neurosci Lett, 2006,406 ( 3 ) :270-275.
  • 9Martinelli BF, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebocontrolled clinical trials [ J ]. Muh Scler,2003,9 (4) : 349-355.
  • 10Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis : a placebo-controlled, double-blind, randomized,muhicentre trial[J]. Lancet,2002,360(9350):2018-2025.

引证文献1

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部